India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja ...

New data from proof-of-concept study provides roadmap for treatment of ovarian cancerCAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.

年终总结能工巧匠，必善用其器。Lonza旗下的电穿孔核转染技术(Nucleofection)无疑是细胞转染的超强利器。电穿孔核转染是一种升级版的转染技术，它克服传统电穿孔方法在转染效率和细胞活力方面的限制。Nucleofector通过优化电场和脉冲条 ...

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b ...

Eterna Therapeutics, Inc. (ERNA) announced Tuesday positive results from a preclinical study on the company's lead cell therapy ...

SunAct Cancer Institute has announced the commencement of Phase 2 clinical trials for Gamma Delta (gd) T-cell therapy, a ...

SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell ...

Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...

Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...